Almatica is focused on the development, acquisition and commercialization of brand named pharmaceutical products. We have a current portfolio of US branded pharmaceutical products covering a wide range of therapeutic areas including: psychiatry, pain management, anti-infectives and cardiovascular related disorders. Almatica is actively pursuing the expansion of its US business through the development of its own pipeline of products designed to make a meaningful improvement over the current standard of care and through the in-licensing and acquisition of external products that are either in-market or in late stage development. The growth of our business is supported by a broad range of in-house commercial, manufacturing and R&D related capabilities.
Almatica Pharma Inc. is a US subsidiary of Alvogen. The parent company Alvogen, is a global, privately owned pharmaceutical company focused on the development, manufacturing and commercialization of generic, brand, OTC and biosimilar products around the world. Alvogen has commercial operations in 35 countries, with regional manufacturing & R&D capabilities in the US, South Korea and Romania.
Alvogen Core Businesses include:
For additional information, visit www.alvogen.com